The present invention includes a method of reducing or inhibiting the kinaseactivity ofC-KIT mutant tyrosine kinase activity in a cell or a subject, and the use ofsuch compound fortreating mutant C-KIT driven cell proliferative disorder(s) in a subjectrelated to using acompound of the present invention:(see above formula)or pharmaceutically acceptable salt thereof.